Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Wesley Woods Geriatric Center
mi
from
Atlanta, GA
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Wesley Woods Geriatric Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Columbus Research Institute
mi
from
Columbus, GA
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Columbus Research Institute
mi
from
Columbus, GA
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Northwestern University PD and Movement Disorders Center
mi
from
Chicago, IL
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Northwestern University PD and Movement Disorders Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Rush University Medical Center
mi
from
Chicago, IL
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
University of Maryland Medical Center
mi
from
Baltimore, MD
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Boston University School of Medicine
mi
from
Boston, MA
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Boston University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
QUEST Research Institute
mi
from
Bingham Farms, MI
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
QUEST Research Institute
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Parkinson's Disease and Movement Disorder Center
mi
from
Albany, NY
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Parkinson's Disease and Movement Disorder Center
mi
from
Albany, NY
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
North Shore Medical Center
mi
from
Manhasset, NY
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
North Shore Medical Center
mi
from
Manhasset, NY
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Neurological Institute of New York
mi
from
New York, NY
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Neurological Institute of New York
mi
from
New York, NY
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
The Neurological Institute
mi
from
Charlotte, NC
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
The Neurological Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Duke Movement Disorders Clinic
mi
from
Durham, NC
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Duke Movement Disorders Clinic
mi
from
Durham, NC
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Pennsylvania Hospital
mi
from
Philadelphia, PA
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Pennsylvania Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Vanderbilt University Medical Center
mi
from
Nashville, TN
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Baylor College of Medicine
mi
from
Houston, TX
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Concord Repatriation General Hospital
mi
from
Concord,
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Concord Repatriation General Hospital
mi
from
Concord,
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
US Medical Information Located in
mi
from
Rockland, MA
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
US Medical Information Located in
mi
from
Rockland, MA
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
The Parkinson's Institute
mi
from
Sunnyvale, CA
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
The Parkinson's Institute
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
Mayo Clinic Florida
mi
from
Jacksonville, FL
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
Emory University
mi
from
Atlanta, GA
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
Northwestern University
mi
from
Chicago, IL
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
Rush University Medical Center
mi
from
Chicago, IL
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
Johns Hopkins University
mi
from
Baltimore, MD
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
Cleveland Clinic
mi
from
Cleveland, OH
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
Baylor College of Medicine Parkinson's Disease Center and Movement Disorders Clinic
mi
from
Houston, TX
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
Baylor College of Medicine Parkinson's Disease Center and Movement Disorders Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated:  3/28/2013
Hospital Clinic de Barcelona
mi
from
Barcelona,
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Status: Enrolling
Updated: 3/28/2013
Hospital Clinic de Barcelona
mi
from
Barcelona,
Click here to add this to my saved trials
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated:  4/2/2013
Cleveland Clinic Florida
mi
from
Weston, FL
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated: 4/2/2013
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated:  4/2/2013
Indiana University Medical Center
mi
from
Indianapolis, IN
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated: 4/2/2013
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated:  4/2/2013
University of Iowa Hospitals
mi
from
Iowa City, IA
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated: 4/2/2013
University of Iowa Hospitals
mi
from
Iowa City, IA
Click here to add this to my saved trials
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated:  4/2/2013
Kansas University Medical Center
mi
from
Kansas City, KA
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated: 4/2/2013
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated:  4/2/2013
University of Maryland School of Medicine
mi
from
Baltimore, MD
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated: 4/2/2013
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated:  4/2/2013
University of Nebraska
mi
from
Omaha, NE
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated: 4/2/2013
University of Nebraska
mi
from
Omaha, NE
Click here to add this to my saved trials
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated:  4/2/2013
Beth Israel Med Ctr
mi
from
New York, NY
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated: 4/2/2013
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated:  4/2/2013
Medical University of Ohio
mi
from
Toledo, OH
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated: 4/2/2013
Medical University of Ohio
mi
from
Toledo, OH
Click here to add this to my saved trials
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated:  4/2/2013
Oregon Health and Science University
mi
from
Portland, OR
PROGENI Family Study of LRRK2
PROGENI Family Study
Status: Enrolling
Updated: 4/2/2013
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease
Status: Enrolling
Updated:  4/16/2013
The Parkinson's Institute
mi
from
Sunnyvale, CA
A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease
Status: Enrolling
Updated: 4/16/2013
The Parkinson's Institute
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Status: Enrolling
Updated:  4/24/2013
Fusion Sleep Center
mi
from
Suwanee, GA
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Status: Enrolling
Updated: 4/24/2013
Fusion Sleep Center
mi
from
Suwanee, GA
Click here to add this to my saved trials
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Status: Enrolling
Updated:  4/24/2013
The New Jersey Neuroscience Institute
mi
from
Edison, NJ
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Status: Enrolling
Updated: 4/24/2013
The New Jersey Neuroscience Institute
mi
from
Edison, NJ
Click here to add this to my saved trials
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Status: Enrolling
Updated:  4/24/2013
UMDNJ Robert Wood Johnson Medical School
mi
from
Piscataway, NJ
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Status: Enrolling
Updated: 4/24/2013
UMDNJ Robert Wood Johnson Medical School
mi
from
Piscataway, NJ
Click here to add this to my saved trials
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Status: Enrolling
Updated:  4/24/2013
University of Pennsylvania Medical School
mi
from
Philadelphia, PA
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Status: Enrolling
Updated: 4/24/2013
University of Pennsylvania Medical School
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease
The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease
Status: Enrolling
Updated:  4/28/2013
New York Institue of Technology
mi
from
Old Westbury, NY
The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease
The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease
Status: Enrolling
Updated: 4/28/2013
New York Institue of Technology
mi
from
Old Westbury, NY
Click here to add this to my saved trials
Nicotine Treatment of Impulsivity in Parkinson's Disease
Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study
Status: Enrolling
Updated:  5/10/2013
Fletcher Allen Health Care/UVM
mi
from
Burlington, VT
Nicotine Treatment of Impulsivity in Parkinson's Disease
Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study
Status: Enrolling
Updated: 5/10/2013
Fletcher Allen Health Care/UVM
mi
from
Burlington, VT
Click here to add this to my saved trials
A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease
Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome
Status: Enrolling
Updated:  5/24/2013
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease
Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome
Status: Enrolling
Updated: 5/24/2013
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
A Phase II, Double-blind, Randomized, Placebo-controlled 4-way Crossover Study to Evaluate the Relative Efficacy and Safety of OC Oral Solution (Oxybutynin and Clonidine) for Sialorrhoea in Patients With Parkinson's Disease
Status: Enrolling
Updated:  6/14/2013
QUEST Research Institute
mi
from
Bingham Farms, MI
A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
A Phase II, Double-blind, Randomized, Placebo-controlled 4-way Crossover Study to Evaluate the Relative Efficacy and Safety of OC Oral Solution (Oxybutynin and Clonidine) for Sialorrhoea in Patients With Parkinson's Disease
Status: Enrolling
Updated: 6/14/2013
QUEST Research Institute
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated:  6/24/2013
Clinical Research Facility
mi
from
Gilbert, AZ
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated: 6/24/2013
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated:  6/24/2013
Clinical Research Facility
mi
from
Oxnard, CA
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated: 6/24/2013
Clinical Research Facility
mi
from
Oxnard, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated:  6/24/2013
Clinical Research Facility
mi
from
Sunnyvale, CA
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated: 6/24/2013
Clinical Research Facility
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated:  6/24/2013
Clinical Research Facility
mi
from
Englewood, CO
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated: 6/24/2013
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated:  6/24/2013
Clinical Research Facility
mi
from
Tampa, FL
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
Status: Enrolling
Updated: 6/24/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials